{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:27Z","timestamp":1786982667297,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13555-024-01293-y","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T11:01:49Z","timestamp":1729854109000},"page":"3071-3081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-8707","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8632-1396","authenticated-orcid":false,"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5664-9789","authenticated-orcid":false,"given":"Siran","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6139-6873","authenticated-orcid":false,"given":"Manish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,25]]},"reference":[{"key":"1293_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182:840\u20138.","journal-title":"Br J Dermatol"},{"key":"1293_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940\u20136.","journal-title":"JAMA Dermatol"},{"key":"1293_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m1590.","journal-title":"BMJ"},{"key":"1293_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360.","journal-title":"JAMA"},{"key":"1293_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fpsyg.2016.00087","volume":"7","author":"J Schwartz","year":"2016","unstructured":"Schwartz J, Evers AW, Bundy C, Kimball AB. Getting under the skin: report from the International Psoriasis Council workshop on the role of stress in psoriasis. Front Psychol. 2016;7:87.","journal-title":"Front Psychol"},{"key":"1293_CR6","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s13555-022-00686-1","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Burge R, Gallo G, et al. A retrospective cohort analysis of treatment patterns over 1\u00a0year in patients with psoriasis treated with ixekizumab or guselkumab. Dermatol Ther. 2022;12:701\u201314.","journal-title":"Dermatol Ther"},{"key":"1293_CR7","unstructured":"American Academy of Dermatology Association. How long will i have to treat my psoriasis? 2023. https:\/\/www.aad.org\/public\/diseases\/psoriasis\/treatment\/medications\/how-long#:~:text=Psoriasis%20medicine%3A%20Psoriasis%20is%20often,clear%20skin%20during%20these%20periods. Accessed 7 Nov 2023."},{"key":"1293_CR8","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","volume":"82","author":"SM Hoy","year":"2022","unstructured":"Hoy SM. Deucravacitinib: first approval. Drugs. 2022;82:1671\u20139.","journal-title":"Drugs"},{"key":"1293_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","volume":"88","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase\u00a03 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88:29\u201339.","journal-title":"J Am Acad Dermatol"},{"key":"1293_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","volume":"88","author":"B Strober","year":"2023","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase\u00a03 program for evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol. 2023;88:40\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1293_CR11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","volume":"79","author":"K McKeage","year":"2019","unstructured":"McKeage K, Duggan S. Risankizumab: first global approval. Drugs. 2019;79:893\u2013900.","journal-title":"Drugs"},{"key":"1293_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/bjd\/ljad252","volume":"189","author":"LF Stein Gold","year":"2023","unstructured":"Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase\u00a0IV study (IMMpulse). Br J Dermatol. 2023;189:540\u201352.","journal-title":"Br J Dermatol"},{"key":"1293_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394:576\u201386.","journal-title":"Lancet"},{"key":"1293_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184:50\u20139.","journal-title":"Br J Dermatol"},{"key":"1293_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392:650\u201361.","journal-title":"Lancet"},{"issue":"1\u2013134","key":"1293_CR16","first-page":"iii","volume":"9","author":"A Glenny","year":"2005","unstructured":"Glenny A, Altman D, Song F, et al. Indirect comparisons of competing interventions. Health Technol Assess. 2005;9(1\u2013134):iii\u2013iv.","journal-title":"Health Technol Assess"},{"key":"1293_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2165\/00019053-200826090-00006","volume":"26","author":"A Sutton","year":"2008","unstructured":"Sutton A, Ades A, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26:753\u201367.","journal-title":"Pharmacoeconomics"},{"key":"1293_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14:417\u201328.","journal-title":"Value Health"},{"key":"1293_CR19","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28:935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"1293_CR20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s13555-024-01143-x","volume":"14","author":"T Torres","year":"2024","unstructured":"Torres T, Sohrt Petersen A, Ivens U, et al. Matching-adjusted indirect comparison of the efficacy at week\u00a032 of tralokinumab and dupilumab in the treatment of moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:983\u201392.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1293_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13555-023-01058-z","volume":"14","author":"K Rand","year":"2024","unstructured":"Rand K, Ramos-Goni JM, Akmaz B, Sole-Feu L, Armario-Hita JC. Matching-adjusted indirect comparison of the long-term efficacy maintenance and adverse event rates of lebrikizumab versus dupilumab in moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024;14:169\u201382.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1293_CR22","unstructured":"Phillippo D, Ades T, Dias S, et al. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. commissioned report. NICE decision support unit. 2016. https:\/\/research-information.bris.ac.uk\/files\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed 16 Sept 2024."},{"key":"1293_CR23","unstructured":"European Network for Health Technology Assessment. D4.3.1: direct and indirect comparisons. 2022. https:\/\/www.eunethta.eu\/wpcontent\/uploads\/2022\/12\/EUnetHTA-21-D4.3.1-Direct-and-indirect-comparisons-v1.0.pdf. Accessed 16 Sept 2024."},{"key":"1293_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15:940\u20137.","journal-title":"Value Health"},{"key":"1293_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00977-1","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Park SH, Patel V, et al. Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis. Dermatol Ther. 2023. https:\/\/doi.org\/10.1007\/s13555-023-00977-1.","journal-title":"Dermatol Ther"},{"key":"1293_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3111\/13696998.2013.768530","volume":"16","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Rao S, Birnbaum HG, et al. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013;16:479\u201389.","journal-title":"J Med Econ"},{"key":"1293_CR27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01393-2018","author":"A Bourdin","year":"2018","unstructured":"Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01393-2018.","journal-title":"Eur Respir J"},{"key":"1293_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1093\/jnci\/djab071","volume":"114","author":"L Wang","year":"2022","unstructured":"Wang L, Paller C, Hong H, et al. Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. J Natl Cancer Inst. 2022;114:191\u2013202.","journal-title":"J Natl Cancer Inst"},{"key":"1293_CR29","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1080\/03007995.2020.1747999","volume":"36","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Haltner A, et al. Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis. Curr Med Res Opin. 2020;36:1157\u201366.","journal-title":"Curr Med Res Opin"},{"key":"1293_CR30","doi-asserted-by":"publisher","first-page":"2169574","DOI":"10.1080\/09546634.2023.2169574","volume":"34","author":"J Signorovitch","year":"2023","unstructured":"Signorovitch J, Diels J, Van Sanden S, et al. Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis. J Dermatol Treat. 2023;34:2169574.","journal-title":"J Dermatol Treat"},{"key":"1293_CR31","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1007\/s13555-023-01034-7","volume":"13","author":"AW Armstrong","year":"2023","unstructured":"Armstrong AW, Warren RB, Zhong Y, et al. Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2023;13:2839\u201357.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1293_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12:167\u201384.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1293_CR33","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13555-021-00511-1","volume":"11","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA, et al. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2021;11:885\u2013905.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01293-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01293-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T22:16:39Z","timestamp":1731449799000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01293-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,25]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01293-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,25]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong is a research investigator, scientific advisor, and\/or speaker for AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, Leo, Lilly, Mindera Health, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Ahmed M. Soliman, Siran Fang, and Manish Patel are full-time employees of AbbVie and may hold AbbVie stock and\/or stock options and patents. Paolo Gisondi has been a consultant and\/or speaker for AbbVie, Almirall, Amgen, Janssen, Leo-pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi, UCB. Bruce Strober has served as a consultant (received honoraria) for AbbVie, Acelyrin, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Kangpu Pharmaceuticals, Bristol-Myers-Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Imagenebio, Janssen, Leo, Eli Lilly, Maruho, Okura, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, and Union Therapeutics. He owns stock options in Connect Biopharma and Mindera Health. He has served as a speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme and as a co-scientific director (consulting fee) and investigator for CorEvitas Psoriasis Registry. He also serves as editor-in-chief (honorarium) for<i> The Journal of Psoriasis and Psoriatic Arthritis<\/i>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study, and each clinical trial included in the analysis, was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and was consistent with International Conference on Harmonization Good Clinical Practice, Good Epidemiology Practices, and applicable regulatory requirements [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ]. This analysis utilized de-identified data from published clinical trial data; thus no ethics committee approval was required. However, each individual trial included in this analysis was approved by independent ethics committees or institutional review boards at each study site and all patients provided written informed consent before enrolling in each clinical trial [\n                      \n                      ,\n                      \n                      ,\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}